Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $21

Benzinga · 10/14 14:13
Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $26 to $21.